Last reviewed · How we verify
Human Albumin 20%
Human Albumin 20% is a Colloid volume expander Small molecule drug developed by Asian Institute of Gastroenterology, India. It is currently in Phase 3 development for Hypovolemia and shock management, Ascites in liver cirrhosis, Albumin replacement in hypoalbuminemia.
Human Albumin 20% acts as a colloid osmotic agent that expands intravascular volume and maintains oncotic pressure to restore fluid balance.
Human Albumin 20% acts as a colloid osmotic agent that expands intravascular volume and maintains oncotic pressure to restore fluid balance. Used for Hypovolemia and shock management, Ascites in liver cirrhosis, Albumin replacement in hypoalbuminemia.
At a glance
| Generic name | Human Albumin 20% |
|---|---|
| Sponsor | Asian Institute of Gastroenterology, India |
| Drug class | Colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Human Albumin 20% is a hyperoncotic solution that increases plasma oncotic pressure, drawing fluid from the interstitial space into the intravascular compartment. This restores circulating blood volume and improves tissue perfusion. It is commonly used in clinical settings to manage hypovolemia, ascites, and conditions requiring rapid plasma volume expansion.
Approved indications
- Hypovolemia and shock management
- Ascites in liver cirrhosis
- Albumin replacement in hypoalbuminemia
Common side effects
- Hypervolemia / fluid overload
- Hypertension
- Allergic reactions
- Fever
- Nausea
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Recombinant Human Serum Albumin in Healthy Subjects (PHASE1)
- Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects (PHASE1)
- Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites (PHASE2, PHASE3)
- Phase II/III of Recombinant Human Serum Albumin (PHASE2, PHASE3)
- Modulation of Cerebral Ischemia by Albumin (PHASE2)
- Strong Albumin Solutions in Patients With Septic Shock (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Albumin 20% CI brief — competitive landscape report
- Human Albumin 20% updates RSS · CI watch RSS
- Asian Institute of Gastroenterology, India portfolio CI
Frequently asked questions about Human Albumin 20%
What is Human Albumin 20%?
How does Human Albumin 20% work?
What is Human Albumin 20% used for?
Who makes Human Albumin 20%?
What drug class is Human Albumin 20% in?
What development phase is Human Albumin 20% in?
What are the side effects of Human Albumin 20%?
Related
- Drug class: All Colloid volume expander drugs
- Manufacturer: Asian Institute of Gastroenterology, India — full pipeline
- Therapeutic area: All drugs in Critical Care / Gastroenterology
- Indication: Drugs for Hypovolemia and shock management
- Indication: Drugs for Ascites in liver cirrhosis
- Indication: Drugs for Albumin replacement in hypoalbuminemia
- Compare: Human Albumin 20% vs similar drugs
- Pricing: Human Albumin 20% cost, discount & access